The ubiquitin-proteasome system - Micro target for macro intervention?

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The ubiquitin-proteasome system is the two sequential labeling and degradation system that accounts for the degradation of 80-90% of all intracellular proteins. Based on the diversity of its substrates, it is integrated in many different biological processes, especially inflammation and cell proliferation. Given the significance of these two processes for primary atherosclerosis and restenosis, the ubiquitin-proteasome system may be an amendable target in cardiovascular therapy. This review provides background information on the ubiquitin-proteasome system, currently available data on its involvement in cardiovascular diseases, and a future perspective on the targeted use proteasome inhibitors, including drug-eluting stents.

Original languageEnglish (US)
Pages (from-to)5-13
Number of pages9
JournalInternational Journal of Cardiovascular Interventions
Volume7
Issue number1
DOIs
StatePublished - 2005

Fingerprint

Proteasome Endopeptidase Complex
Ubiquitin
Biological Phenomena
Proteasome Inhibitors
Drug-Eluting Stents
Atherosclerosis
Cardiovascular Diseases
Cell Proliferation
Inflammation
Proteins
Therapeutics

Keywords

  • Atherosclerosis
  • Inflammation
  • Neointima
  • Pathology

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Radiology Nuclear Medicine and imaging

Cite this

@article{b1070612739543588e5eaf2b594c90a1,
title = "The ubiquitin-proteasome system - Micro target for macro intervention?",
abstract = "The ubiquitin-proteasome system is the two sequential labeling and degradation system that accounts for the degradation of 80-90{\%} of all intracellular proteins. Based on the diversity of its substrates, it is integrated in many different biological processes, especially inflammation and cell proliferation. Given the significance of these two processes for primary atherosclerosis and restenosis, the ubiquitin-proteasome system may be an amendable target in cardiovascular therapy. This review provides background information on the ubiquitin-proteasome system, currently available data on its involvement in cardiovascular diseases, and a future perspective on the targeted use proteasome inhibitors, including drug-eluting stents.",
keywords = "Atherosclerosis, Inflammation, Neointima, Pathology",
author = "Joerg Herrmann and Aaron Ciechanover and Lerman, {Lilach O} and Amir Lerman",
year = "2005",
doi = "10.1080/14628840510011234",
language = "English (US)",
volume = "7",
pages = "5--13",
journal = "Acute Cardiac Care",
issn = "1748-2941",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - The ubiquitin-proteasome system - Micro target for macro intervention?

AU - Herrmann, Joerg

AU - Ciechanover, Aaron

AU - Lerman, Lilach O

AU - Lerman, Amir

PY - 2005

Y1 - 2005

N2 - The ubiquitin-proteasome system is the two sequential labeling and degradation system that accounts for the degradation of 80-90% of all intracellular proteins. Based on the diversity of its substrates, it is integrated in many different biological processes, especially inflammation and cell proliferation. Given the significance of these two processes for primary atherosclerosis and restenosis, the ubiquitin-proteasome system may be an amendable target in cardiovascular therapy. This review provides background information on the ubiquitin-proteasome system, currently available data on its involvement in cardiovascular diseases, and a future perspective on the targeted use proteasome inhibitors, including drug-eluting stents.

AB - The ubiquitin-proteasome system is the two sequential labeling and degradation system that accounts for the degradation of 80-90% of all intracellular proteins. Based on the diversity of its substrates, it is integrated in many different biological processes, especially inflammation and cell proliferation. Given the significance of these two processes for primary atherosclerosis and restenosis, the ubiquitin-proteasome system may be an amendable target in cardiovascular therapy. This review provides background information on the ubiquitin-proteasome system, currently available data on its involvement in cardiovascular diseases, and a future perspective on the targeted use proteasome inhibitors, including drug-eluting stents.

KW - Atherosclerosis

KW - Inflammation

KW - Neointima

KW - Pathology

UR - http://www.scopus.com/inward/record.url?scp=20344373169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20344373169&partnerID=8YFLogxK

U2 - 10.1080/14628840510011234

DO - 10.1080/14628840510011234

M3 - Article

C2 - 16019609

AN - SCOPUS:20344373169

VL - 7

SP - 5

EP - 13

JO - Acute Cardiac Care

JF - Acute Cardiac Care

SN - 1748-2941

IS - 1

ER -